These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 11996648)
1. Enzyme replacement therapy for the mucopolysaccharide storage disorders. Kakkis ED Expert Opin Investig Drugs; 2002 May; 11(5):675-85. PubMed ID: 11996648 [TBL] [Abstract][Full Text] [Related]
2. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I. Dickson P; Peinovich M; McEntee M; Lester T; Le S; Krieger A; Manuel H; Jabagat C; Passage M; Kakkis ED J Clin Invest; 2008 Aug; 118(8):2868-76. PubMed ID: 18654665 [TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement therapy in feline mucopolysaccharidosis I. Kakkis ED; Schuchman E; He X; Wan Q; Kania S; Wiemelt S; Hasson CW; O'Malley T; Weil MA; Aguirre GA; Brown DE; Haskins ME Mol Genet Metab; 2001 Mar; 72(3):199-208. PubMed ID: 11243725 [TBL] [Abstract][Full Text] [Related]
4. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. Muenzer J Mol Genet Metab; 2014 Feb; 111(2):63-72. PubMed ID: 24388732 [TBL] [Abstract][Full Text] [Related]
5. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Kakkis ED; McEntee MF; Schmidtchen A; Neufeld EF; Ward DA; Gompf RE; Kania S; Bedolla C; Chien SL; Shull RM Biochem Mol Med; 1996 Aug; 58(2):156-67. PubMed ID: 8812735 [TBL] [Abstract][Full Text] [Related]
6. [Overview of enzyme replacement therapy in mucopolysaccharidosis]. Fouilhoux A; Guffon N Presse Med; 2007 Mar; 36 Spec No 1():1S96-9. PubMed ID: 17546776 [TBL] [Abstract][Full Text] [Related]
7. Substrate accumulation and extracellular matrix remodelling promote persistent upper airway disease in mucopolysaccharidosis patients on enzyme replacement therapy. Pal AR; Mercer J; Jones SA; Bruce IA; Bigger BW PLoS One; 2018; 13(9):e0203216. PubMed ID: 30226843 [TBL] [Abstract][Full Text] [Related]
8. Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I. Braunlin EA; Berry JM; Whitley CB Am J Cardiol; 2006 Aug; 98(3):416-8. PubMed ID: 16860035 [TBL] [Abstract][Full Text] [Related]
9. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Dickson P; McEntee M; Vogler C; Le S; Levy B; Peinovich M; Hanson S; Passage M; Kakkis E Mol Genet Metab; 2007 May; 91(1):61-8. PubMed ID: 17321776 [TBL] [Abstract][Full Text] [Related]
10. Characterization of pulmonary function impairments in patients with mucopolysaccharidoses--changes with age and treatment. Lin SP; Shih SC; Chuang CK; Lee KS; Chen MR; Niu DM; Chiu PC; Lin SJ; Lin HY Pediatr Pulmonol; 2014 Mar; 49(3):277-84. PubMed ID: 23401495 [TBL] [Abstract][Full Text] [Related]
11. Laronidase for the treatment of mucopolysaccharidosis type I. Clarke LA Expert Rev Endocrinol Metab; 2011 Nov; 6(6):755-768. PubMed ID: 30780865 [TBL] [Abstract][Full Text] [Related]
12. Neurochemical characterization of canine alpha-L-iduronidase deficiency disease (model of human mucopolysaccharidosis I). Constantopoulos G; Shull RM; Hastings N; Neufeld EF J Neurochem; 1985 Oct; 45(4):1213-7. PubMed ID: 3928817 [TBL] [Abstract][Full Text] [Related]
13. Galsulfase: arylsulfatase B, BM 102, recombinant human arylsulfatase B, recombinant human N-acetylgalactosamine-4-sulfatase, rhASB. Drugs R D; 2005; 6(5):312-5. PubMed ID: 16128602 [TBL] [Abstract][Full Text] [Related]
14. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Kakkis E; McEntee M; Vogler C; Le S; Levy B; Belichenko P; Mobley W; Dickson P; Hanson S; Passage M Mol Genet Metab; 2004; 83(1-2):163-74. PubMed ID: 15464431 [TBL] [Abstract][Full Text] [Related]
15. Enzyme replacement therapy for the management of the mucopolysaccharidoses. Wraith JE Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S63-5. PubMed ID: 20040314 [TBL] [Abstract][Full Text] [Related]
16. Advances in the Development of Pharmacological Chaperones for the Mucopolysaccharidoses. Losada Díaz JC; Cepeda Del Castillo J; Rodriguez-López EA; Alméciga-Díaz CJ Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905715 [TBL] [Abstract][Full Text] [Related]
17. Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I. Kakkis E; Lester T; Yang R; Tanaka C; Anand V; Lemontt J; Peinovich M; Passage M Proc Natl Acad Sci U S A; 2004 Jan; 101(3):829-34. PubMed ID: 14715900 [TBL] [Abstract][Full Text] [Related]